MDG1.F Stock Surges 168% on High Volume: Medigene AG Liquidation Update

MDG1.F stock exploded 168.25% on Friday, closing at €0.0338 on XETRA. Medigene AG, the Munich-based biotech company, is in liquidation of remaining assets after years of T-cell therapy development. The dramatic spike caught traders’ attention with 3,107 shares traded, well below the 6,925 average daily volume. This represents a volatile swing from the previous close of €0.0126. The stock remains deeply underwater from its €0.219 year high, reflecting the company’s challenging journey in the healthcare sector.

What Triggered the MDG1.F Stock Price Jump Today

The 168% surge in MDG1.F stock price came without major news announcements, suggesting technical or short-covering activity. The stock opened at €0.02 and climbed to the day’s high of €0.0338. Volume remained light at 3,107 shares, indicating limited liquidity in this micro-cap biotech name. Medigene AG’s last earnings announcement occurred on March 26, 2026. The company’s liquidation status means price movements often reflect asset valuation changes or speculative positioning rather than operational improvements. Traders should note the extreme volatility typical of stocks in wind-down phases.

MDG1.F Stock Performance: Year-to-Date and Long-Term Trends

Year-to-date, MDG1.F stock is up 35.2%, but this masks severe long-term deterioration. Over one year, the stock has crashed 80.69%. The three-year decline stands at 99.01%, and the five-year loss reaches 99.54%. The stock’s all-time performance shows a staggering 99.99% decline from peak levels. The 50-day moving average sits at €0.032684, while the 200-day average is €0.0520475. These metrics reveal a stock in structural decline. Track MDG1.F on Meyka for real-time updates on this liquidation process.

MDG1.F Stock Valuation: Key Metrics and Financial Health

Medigene AG trades at a price-to-book ratio of 0.0136, suggesting extreme distress valuation. The company’s market cap stands at just €498,131, making it a micro-cap equity. Earnings per share are deeply negative at -€1.21, with a PE ratio of -0.03. The price-to-sales ratio of 0.0542 indicates the stock trades at a fraction of revenue. Book value per share is €1.6289, yet the stock trades far below this. Cash per share of €1.2892 provides some cushion. These metrics confirm Medigene AG is in severe financial distress, with liquidation as the likely outcome.

Market Sentiment: Trading Activity and Liquidation Concerns

Trading Activity: The relative volume of 0.449 shows today’s trading was 45% of average, indicating weak participation despite the price spike. Money Flow Index at 66.40 suggests buying pressure, though absolute volume remains minimal. The Stochastic indicator (%K: 33.09, %D: 20.21) signals oversold conditions, potentially explaining the bounce. Liquidation Concerns: Medigene AG explicitly states it is in liquidation of remaining assets. This means shareholder recovery depends entirely on asset sales and debt settlement. The company’s negative operating margins of -268% and negative return on equity of -55.69% confirm operational collapse. Investors should treat this as a distressed situation with high risk of total loss.

MDG1.F Stock Grade and Technical Outlook

Meyka AI rates MDG1.F with a grade of C+ with a HOLD suggestion. The score of 58.99 reflects poor fundamentals, sector underperformance, and negative growth metrics. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors. Technically, the RSI of 50.55 shows neutral momentum. The Commodity Channel Index at -40.92 indicates weakness. Bollinger Bands (upper: €0.04, lower: €0.03) show tight trading ranges. The Average True Range of €0.01 reflects extreme price volatility typical of illiquid stocks.

Healthcare Sector Context: How MDG1.F Compares

The Healthcare sector averages a PE ratio of 29.8 and price-to-book of 6.55. MDG1.F’s PE of -0.03 and PB of 0.0136 are catastrophically lower, highlighting its distressed status. Sector leaders like Eli Lilly (LLY.DE) trade at €783.50 with strong fundamentals. The sector’s average net margin is -22.5%, yet Medigene’s -268% margin is far worse. Sector ROE averages 17.11%, while Medigene’s is -55.69%. This comparison underscores that MDG1.F is not a typical healthcare play but rather a liquidation situation. The company’s previous focus on T-cell cancer therapies shows promise in concept, but execution failed to deliver shareholder value.

Final Thoughts

MDG1.F stock’s 168% spike on Friday reflects extreme volatility in a micro-cap biotech undergoing liquidation. The €0.0338 close represents a technical bounce in a deeply distressed security, not a fundamental recovery. Medigene AG’s negative earnings, collapsing margins, and explicit liquidation status signal high risk. The stock’s 99.99% all-time decline and 80.69% one-year loss demonstrate the severity of value destruction. With a market cap under €500,000 and minimal trading volume, liquidity is virtually nonexistent. Investors should recognize this as a speculative, high-risk situation suitable only for those comfortable with potential total loss. The company’s asset liquidation process will determine final shareholder recovery. Monitor developments closely, as distressed situations can move rapidly. This is not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.